Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 256

Sort by

Sort Order Select

Journal Articles

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Blood (2024) 144 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2024-212970

Published: 2024

Journal Articles

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Marion Aymard, Morgane Cheminant, Roch Houot, Anne Cuozzo, Elodie Gat, Catherine Thieblemont, Laure Ricard, Louise Roulin, Krimo Bouabdallah, Violaine Safar, Stephanie Guidez, Amandine Fayard, Gabriel Brisou, Loic Ysebaert, Olivier Hermine, Benoit Tessoulin, Charles Herbaux, Steven Le Gouill, Clementine Sarkozy

Blood (2024) 144 (Supplement 1): 239.

https://doi.org/10.1182/blood-2024-198920

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

Carmod, an Open-Label, Multicenter, Proof of Concept, Phase II Trial, Investigating the Safety and Efficacy of Golcadomide in Post-CART for Patients with Relapsed/Refractory High-Risk Aggressive Large B-Cell Lymphoma

Catherine Thieblemont, François-Xavier Gros, Sandrine Roulland, Salim Kanoun, Veronique Meignin, Celine Row, Thierry Lamy, Emmanuel Gomez, Karin Tarte, Gabriel Brisou

Blood (2024) 144 (Supplement 1): 7226.

https://doi.org/10.1182/blood-2024-207843

Published: 2024

Journal Articles

Early Metabolic Response and Tmtv Are Key Predictors of Control of Relapse/Refractory Follicular Lymphoma Treated with CAR-T Cells : Preliminary Results from the French Descar-T Registry

Yassine Al Tabaa, Xavier Pallard, Loic Ysebaert, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Guillaume Cartron, Catherine Thieblemont, Didier Blaise, Cedric Rossi, Francoise Kraeber-Bodere, Benoit Tessoulin, Fabien Le Bras, Olivier Hermine, Emelie Van Zele, Vivien Dupont, Romain Ricci

Blood (2024) 144 (Supplement 1): 7131.

https://doi.org/10.1182/blood-2024-200968

Published: 2024

Journal Articles

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Catherine S. Diefenbach, Andrew D. Zelenetz, Charles Herbaux, Monica Tani, Roch Houot, Mariana Bastos-Oreiro, Hervé Tilly, Thomas Gastinne, Catherine Thieblemont, Wilfred Leung, Katerina Hatzi, Murali Kesavan, Simona Barlera, Michelle Boyer, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 577.

https://doi.org/10.1182/blood-2024-198624

Published: 2024

Journal Articles

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Blood (2024) 144 (Supplement 1): 575.

https://doi.org/10.1182/blood-2024-202446

Published: 2024

Journal Articles

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Franck Morschhauser, David Belada, Johannes Duell, Wojciech Jurczak, Tae Min Kim, Won Seog Kim, Takahiro Kumode, Javier López Jiménez, Caressa Meert, Sergio Ortegon Alcaide, Catherine Thieblemont, Yajian Jiang, Mina Khoshdeli, Yanli Wang, Evelyn Guo, Daniela Hoehn, Sherida Woei-A-Jin

Blood (2024) 144 (Supplement 1): 867.

https://doi.org/10.1182/blood-2024-199271

Published: 2024

Journal Articles

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Blood (2024) 144 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2024-200614

Published: 2024

Journal Articles

Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Thomas Hueso, Jessy Alchidiac, Maria-Rosa Ghigna, Arnaud Pages, Cyril Quivoron, Camille Bigenwald, Loic Renaud, Cristina Castilla-Llorente, Alexandre Eeckhoutte, Serge Bologna, Veronique Morel, Vincent Delwail, Pierre Feugier, Catherine Thieblemont, Olivier Bernard, Peggy Dartigues, Christophe Massard, Vincent Ribrag, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 474.

https://doi.org/10.1182/blood-2024-203664

Published: 2024

Journal Articles

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

Neha Dixit, Binhuan Wang, Kevin Zhao, Catherine Thieblemont, Irit Avivi Mazza, David Lavie, Abraham Avigdor, Carlos Grande Garcia, Andrew J. Steele, Mostafa Seliem, Pegah Jafarinasabian, Edith Szafer Glusman

Blood (2024) 144 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2024-200395

Published: 2024

Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont

Blood (2024) 144 (Supplement 1): 2349.

https://doi.org/10.1182/blood-2024-203994

Published: 2024

Journal Articles

Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study

Mary B. Callanan, Caroline Milin, Marie-Helene Delfau-Larue, Clément Bailly, Clémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, Emmanuel Gyan, Krimo Bouabdallah, Remy Gressin, Gandhi Damaj, Olivier Casasnovas, Vincent Ribrag, Samuel Griolet, Barbara Burroni, Olivier Hermine, Elizabeth A. Macintyre, Steven Le Gouill

Blood (2024) 144 (Supplement 1): 1596.

https://doi.org/10.1182/blood-2024-208081

Published: 2024

Journal Articles

CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry

Blood (2024) 144 (Supplement 1): 3124.

https://doi.org/10.1182/blood-2024-205388

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Ronit Gurion, Irit Avivi Mazza, Catherine Thieblemont, Won Seog Kim, Andras Masszi, Alejandro Martín García-Sancho, Zsolt Nagy, Benoit Tessoulin, Ana Jimenez Ubieto, Po-Shen Ko, Daniel Alan Kerr, II, Edwin E. Jeng, Satya Siddani, Neha Joshi, Neha Dixit, Mariana Sacchi, Pegah Jafarinasabian, Abraham Avigdor

Blood (2024) 144 (Supplement 1): 3110.

https://doi.org/10.1182/blood-2024-199301

Published: 2024

Journal Articles

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

Tycel J. Phillips, Michael Roost Clausen, Wojciech Jurczak, Tae Min Kim, Kim Linton, Chan Y Cheah, Jieying Jiang, Kubra Karagoz, Mohammad Atiya, Christian Eskelund, Han Si, Edith Szafer Glusman, Andrew J. Steele, Charles Kearns, Catherine Thieblemont

Blood (2024) 144 (Supplement 1): 3115.

https://doi.org/10.1182/blood-2024-199799

Published: 2024

Journal Articles

Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials

Jean-Marie Michot, Cédric Portugues, Lucie Oberic, Fabrice Jardin, Vincent Delwail, Vincent Camus, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Frederic Peyrade, Hervé Tilly

Blood (2024) 144 (Supplement 1): 4467.

https://doi.org/10.1182/blood-2024-202588

Published: 2024

Journal Articles

Prognosis of the IGLV3-21 R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort

Merieme Bensalah, Amal Messaoudi, Carole Fleury, Giulia Tueur, Rémi Letestu, Marine Armand, Sabine Brechignac, Sarah Ivanoff, Valérie Vidal, Ramy Rahmé, Chadi Al Nawakil, Thorsten Braun, Catherine Thieblemont, Cymbalista Florence, Vincent Levy, Fanny Baran-Marszak, Grégory Lazarian

Blood (2024) 144 (Supplement 1): 3241.

https://doi.org/10.1182/blood-2024-200665

Published: 2024

Journal Articles

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4480.

https://doi.org/10.1182/blood-2024-198714

Published: 2024

Journal Articles

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Catherine Thieblemont, Yasmin H. Karimi, Chan Y Cheah, Michael Roost Clausen, Kim Linton, Tycel J. Phillips, Franck Morschhauser, Martin Hutchings, Rebekah Conlon, Saurabh Mukhopadhyay, Aurelie Le Maitre, Yu Deng, Mariana Sacchi, Thomas Doerr, Minh Dinh, William Palo, Loretta Nastoupil

Blood (2024) 144 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2024-200957

Published: 2024

NARROW

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Carmod, an Open-Label, Multicenter, Proof of Concept, Phase II Trial, Investigating the Safety and Efficacy of Golcadomide in Post-CART for Patients with Relapsed/Refractory High-Risk Aggressive Large B-Cell Lymphoma

Early Metabolic Response and Tmtv Are Key Predictors of Control of Relapse/Refractory Follicular Lymphoma Treated with CAR-T Cells : Preliminary Results from the French Descar-T Registry

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study

CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials

Prognosis of the IGLV3-21 R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only